MicroRNAs, whose discovery was recognized with the 2025 Nobel Prize in Physiology or Medicine, are central regulators of gene ...
The process of “epigenetic memory” in nerve cells plays a key role in learning ability, memory function, and healthy brain ...
CLASSIC enables large-scale testing of complex DNA circuits in human cells, advancing data-driven synthetic biology.
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year ...
Plant regeneration relies on a delicate balance between stem cell renewal and differentiation, yet the evolutionary origin ...
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a ...
Hosted on MSN
Taysha Gene (TSHA) hovers around its 52-week high as it continues to advance Rett syndrome program
With strong 1-year returns and upside potential, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. As of December 17, ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene-writing program, inking a deal that lets it in on a prospect for alpha-1 antitrypsin deficiency (AATD) through a $150 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback